Amicus Therapeutics, GlaxoSmithKline deal

Amicus and GlaxoSmithKline amended a 2010 deal that gave the pharma exclusive, worldwide rights to Amicus' Fabry's disease therapy migalastat. Amicus will now be responsible for U.S. commercialization of migalastat as monotherapy, in combination with approved enzyme replacement therapies, and a co-formulation of migalastat with a preclinical GSK enzyme replacement (see BioCentury, Nov. 1, 2010).

Starting in 2013, Amicus will pay 40% of development costs, which is up from 25% under the original deal. In addition, GSK is now eligible to receive up to $55 million in U.S. regulatory and commercialization milestones from Amicus. ...